Celldex Therapeutics, Inc. Logo

Email this page: News Release

Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO

 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by Celldex Therapeutics, Inc. for any marketing purposes.

Send:       


 
This helps Celldex Therapeutics, Inc. prevent automated submissions.